In parallel to the broad mechanistic and pharmacokinetic studies on the antitumor efficacy and mode of action of tTF-NGR as the lead structure of a new class of antitumor fusion proteins, studies in xenograft-tumor bearing athymic mice provided some predictive safety information for the human situation. This evidence concerns the gene RHOH and neoplasm.